Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has been evaluated by 13 analysts over the last three months, with diverse opinions ranging from bullish to bearish. The average 12-month price target for REGN is $924.23, up 5.8% from the previous target of $873.57. Analysts from firms like Cantor Fitzgerald, Truist Securities, TD Cowen, Jefferies, Deutsche Bank, Piper Sandler, RBC Capital, Morgan Stanley, and Raymond James have provided updates, with some maintaining their ratings and others raising or lowering their price targets. Regeneron is known for its products in various medical fields and has shown strong financial health with a high net margin and ROE, a positive revenue trend, and a low debt-to-equity ratio.
January 09, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received varied analyst ratings with an updated average 12-month price target of $924.23. The company's strong financial indicators suggest a positive outlook, potentially influencing the stock price favorably in the short term.
The increase in the average price target and the strong financial performance of Regeneron Pharmaceuticals, including a high net margin and ROE, suggest a positive sentiment among analysts, which could lead to a short-term increase in the stock price. However, the mixed ratings indicate that there is some disagreement among analysts, which could temper the impact.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100